Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the efficacy of switching to aflibercept in diabetic macular edema (DME) with suboptimalresponse to previous anti-vascular endothelial growth factor (anti-VEGF) injections. Methods: A prospective interventional case series study recruited patients from a single center diagnosedwith DME with suboptimal response to anti-VEGF injections. Three consecutive monthly injections of afliberceptwere performed. The primary outcome measure was mean change in visual acuity after switching toaflibercept. Results: Forty-two patients (42 eyes) were included. Baseline logarithm of the minimum angle of resolution(logMAR) visual acuity was 0.87 ± 0.23 and improved significantly to 0.62 ± 0.29, 0.56 ± 0.34, and 0.46 ±0.35 at 1, 2, and 3 months, respectively, after the first injection. Mean baseline retinal thickness was 451.57± 107.09 μm and decreased significantly at 1, 2, and 3 months after switching to aflibercept (346.52 ± 79.03,328.24 ± 81.98, and 313.71 ± 85.79 μm, respectively). Both visual improvement and mean change in retinalthickness were significant in patients with pre-aflibercept best-corrected visual acuity less than 1.0 logMARbut were not significant in patients with best-corrected visual acuity more than 1.0 logMAR. Conclusions: Switching to aflibercept in DME patients with an unsatisfactory response to previous anti-VEGFinjections provided acceptable short-term visual and retinal architectural improvement.
Abstract
Purpose: To evaluate the efficacy of switching to aflibercept in diabetic macular edema (DME) with suboptimalresponse to previous anti-vascular endothelial growth factor (anti-VEGF) injections. Methods: A prospective interventional case series study recruited patients from a single center diagnosedwith DME with suboptimal response to anti-VEGF injections. Three consecutive monthly injections of afliberceptwere performed. The primary outcome measure was mean change in visual acuity after switching toaflibercept. Results: Forty-two patients (42 eyes) were included. Baseline logarithm of the minimum angle of resolution(logMAR) visual acuity was 0.87 ± 0.23 and improved significantly to 0.62 ± 0.29, 0.56 ± 0.34, and 0.46 ±0.35 at 1, 2, and 3 months, respectively, after the first injection. Mean baseline retinal thickness was 451.57± 107.09 μm and decreased significantly at 1, 2, and 3 months after switching to aflibercept (346.52 ± 79.03,328.24 ± 81.98, and 313.71 ± 85.79 μm, respectively). Both visual improvement and mean change in retinalthickness were significant in patients with pre-aflibercept best-corrected visual acuity less than 1.0 logMARbut were not significant in patients with best-corrected visual acuity more than 1.0 logMAR. Conclusions: Switching to aflibercept in DME patients with an unsatisfactory response to previous anti-VEGFinjections provided acceptable short-term visual and retinal architectural improvement.
참고문헌 (36)
- Ting DS, "Diabetic retinopathy : global prevalence, major risk factors, screening practices and public health challenges : a review", Clin Exp Ophthalmol, 44, pp.260~277 (2016)
- Yau JW, "Global prevalence and major risk factors of diabetic retinopathy", Diabetes Care, 35, pp.556~564 (2012)
- "Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group", Arch Ophthalmol, 103, pp.1796~1806 (1985)
- Nguyen QD, "Ranibizumab for diabetic macular edema : results from 2 phase III randomized trials : RISE and RIDE", Ophthalmology, 119, pp.789~801 (2012)
- Rajendram R, "A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy(BOLT)in the management of diabetic macular edema : 24-month data : report 3", Arch Ophthalmol, 130, pp.972~979 (2012)
- Brown DM, "Intravitreal aflibercept for diabetic macular edema : 100-week results from the VISTA and VIVID studies", Ophthalmology, 122, pp.2044~2052 (2015)
- Do DV, "One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema", Ophthalmology, 119, pp.1658~1665 (2012)
- Diabetic Retinopathy Clinical Research Network, "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema", N Engl J Med, 372, pp.1193~1203 (2015)
- Rahimy E, "Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema", Am J Ophthalmol, 164, pp.118~127 (2016)
- Bahrami B, "Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema", Graefes Arch Clin Exp Ophthalmol, 255, pp.1133~1140 (2017)
- Chen YY, "Intravitreal aflibercept for patients with diabetic macular edema refractory to bevacizumab or ranibizumab: analysis of response to aflibercept", Asia Pac J Ophthalmol(Phila), 6, pp.250~255 (2017)
- Papadopoulos N, "Binding and neutralization of vascular endothelial growth factor(VEGF)and related ligands by VEGF Trap, ranibizumab and bevacizumab", Angiogenesis, 15, pp.171~185 (2012)
- Moradi A, "Vascular endothelial growth factor trap-eye(Aflibercept)for the management of diabetic macular edema", World J Diabetes, 4, pp.303~309 (2013)
- Stewart MW, "Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept(vascular endothelial growth factor Trap-eye)", Retina, 32, pp.434~457 (2012)
- Pacella F, "An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy", Int J Ophthalmol, 9, pp.1427~1432 (2016)
- Schaal S, "Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration", Ophthalmology, 115, pp.2199~2205 (2008)
- Gokce G, "Efficacy of aflibercept on exudative age-related macular degeneration in patients exhibiting complete ranibizumab resistance and tachy phylaxis", Arq Bras Of talmol, 79, pp.384~389 (2016)
- Arjamaa O, "Resistance, not tachyphylaxis or tolerance", Br J Ophthalmol, 96, pp.1153~1154 (2012)
- Binder S, "Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?", Br J Ophthalmol, 96, pp.1~2 (2012)
- Forooghian F, "Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis", Acta Ophthalmol, 89, pp.e206~7 (2011)
- Praidou A, "Angiogenic growth factors and their inhibitors in diabetic retinopathy", Curr Diabetes Rev, 6, pp.304~312 (2010)
- Krizova L, "Correlation of vitreous vascular endothelial growth factor and uric acid concentration using optical coherence tomography in diabetic macular edema", J Ophthalmol, 2015, pp.478509~ (2015)
- Frederick L. Ferris, "Evaluating Effects of Switching Anti–Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema", JAMA Ophthalmology, 135(2), pp.145~ (2017), American Medical Association (AMA)[DOI]
- Khan Z, "Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy : meta-analysis and clinical implications", Ophthalmic Surg Lasers Imaging Retina, 48, pp.160~166 (2017)
- Maturi RK, "A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy", Retina, 35, pp.1604~1614 (2015)
- Ghassemi F, "Outcomes of vitrectomy, membranectomy and internal limiting membrane peeling in patients with refractory diabetic macular edema and non-tractional epiretinal membrane", J Curr Ophthalmol, 28, pp.199~205 (2016)
- Pieramici DJ, "Visual and anatomic outcomes in patients with diabetic macular edema with limited initial anatomic response to ranibizumab in RIDE and RISE", Ophthalmology, 123, pp.1345~1350 (2016)
- Prabhu M, "A hospital based study regarding awareness of association between glycosylated haemoglobin and severity of diabetic retinopathy in type 2 diabetic individuals", J Clin Diagn Res, 10, pp.NC01~NC04 (2016)
- Wells JA, "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema : two-year results from a comparative effectiveness randomized clinical trial", Ophthalmology, 123, pp.1351~1359 (2016)
- Dugel PU, "Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials", Clin Ophthalmol, 10, pp.1103~1110 (2016)
- Wells JA, "Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema", JAMA Ophthalmol, 134, pp.127~134 (2016)
- Eliwa TF, "Outer retinal layer thickness as good visual predictor in patients with diabetic macular edema", Retina, 38, pp.805~811 (2018)
- Sun JK, "Neural retinal disorganization as a robust marker of visual acuity in current and resolved diabetic macular edema", Diabetes, 64, pp.2560~2570 (2015)
- Lee J, "Optical coherence tomography angiography of DME and its association with anti-VEGF treatment response", Ophthalmology, 123, pp.2368~2375 (2016)
- Wong Y, "Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema", Graefes Arch Clin Exp Ophthalmol, 255, pp.733~742 (2017)
- Sadiq MA, "Effect of vitreomacular adhesion on treatment outcomes in the ranibizumab for edema of the macula in diabetes(READ-3)study", Ophthalmology, 123, pp.324~329 (2016)